Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune activation, smoking, and vaccine response.
Younas M, Carrat F, Desaint C, Launay O, Corbeau P; ANRS HB03 VIHVAC-B Trial Group. Younas M, et al. Among authors: launay o. AIDS. 2017 Jan 2;31(1):171-173. doi: 10.1097/QAD.0000000000001311. AIDS. 2017. PMID: 27835620 Free article.
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Launay O, et al. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.
Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard PM, Bélarbi L, Guérin C, Dimet J, Williams V, Krivine A, Salmon D, Lortholary O, Rey D; HEPAVAC Study Group1. Launay O, et al. J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):272-5. doi: 10.1097/QAI.0b013e318183a9c0. J Acquir Immune Defic Syndr. 2008. PMID: 18845961 Clinical Trial.
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group. Salmon-Céron D, et al. Among authors: launay o. AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566. AIDS. 2010. PMID: 20625264 Clinical Trial.
[Flu vaccine and auto-immune and/or inflammatory diseases].
Duchet-Niedziolka P, Hanslik T, Mouthon L, Guillevin L, Launay O. Duchet-Niedziolka P, et al. Among authors: launay o. Presse Med. 2011 Mar;40(3):248-52. doi: 10.1016/j.lpm.2010.12.003. Epub 2011 Jan 12. Presse Med. 2011. PMID: 21232908 French.
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial.
Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial. Launay O, et al. JAMA. 2011 Apr 13;305(14):1432-40. doi: 10.1001/jama.2011.351. JAMA. 2011. PMID: 21486976 Clinical Trial.
487 results